JCM
ALXN

Jafra Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Jafra Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-22,500
Closed -$2.69M – 116
2017
Q4 		$2.69M Buy
+22,500
New +$2.74M 0.76% 37
2017
Q3 		– Sell
-8,826
Closed -$1.07M – 101
2017
Q2 		$1.07M Buy
8,826
+4,826
+121% +$562K 0.4% 63
2017
Q1 		$485K Buy
4,000
+1,000
+33% +$129K 0.2% 58
2016
Q4 		$367K Buy
+3,000
New +$367K 0.31% 60

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jafra Capital Management's ALXN Position: Q1 2018 in Review

Jafra Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 22,500 shares — an estimated $2.69M sold.

Jafra Capital Management first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $2.69M in Q4 2017. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Jafra Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Jafra Capital Management sold 22,500 Alexion Pharmaceuticals shares in Q1 2018, an estimated $2.69M.
  • Jafra Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Jafra Capital Management's Alexion Pharmaceuticals position peaked at $2.69M in Q4 2017.
  • 597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Jafra Capital Management's 13F filing for Q1 2018, filed 23 Apr 2018.